Soligenix announces successful protection using a bivalent thermostabilized filovirus vaccine

Princeton, n.j., dec. 2, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today 100% protection of non-human primates (nhps) against lethal sudan ebolavirus (sudv) challenge using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with water immediately prior to use.
SNGX Ratings Summary
SNGX Quant Ranking